SecBot SecBot
PRESS-RELEASE ·Filed May 31, 2026

REPL

Replimune, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The data de-risk RP2 in uveal melanoma, a high-unmet-need indication with a 33.3% ORR and durable responses. Monitor enrollment updates and interim data from the ongoing Phase 2/3 trial (NCT06581406). The stock may re-rate on positive regulatory milestones, but no BLA or NDA is imminent.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.00
T+0 close · May 31, 2026 · via day close
Latest settled
+75.56%
T+60 · $15.80
Vs SPY
+74.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $9.00entry
  2. T+1 · 6mo ago −1.44%α −1.59% · $8.87
  3. T+5 · 5mo ago +5.22%α +7.97% · $9.47
  4. T+20 · 5mo ago +23.00%α +24.30% · $11.07
  5. T+60 · 3mo ago +75.56%α +74.32% · $15.80

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing durable responses in heavily pretreated advanced solid tumors, including a 33.3% ORR in uveal melanoma. The data support an ongoing randomized Phase 2/3 trial in uveal melanoma, but the filing is a clinical-stage update without regulatory approval or financial results, making it a notable but non-definitive catalyst.

Key Facts

  • Phase 1 FIH study enrolled 85 heavily pretreated patients (median 2 prior lines; 42% prior ICI therapy).
  • RP2 monotherapy ORR: 19.0% (4/21 evaluable); RP2 + nivolumab ORR: 19.1% (9/47 evaluable).
  • Pooled ORR in uveal melanoma (where Phase 2/3 is enrolling): 33.3%.
  • Median duration of response not reached in monotherapy (range 11.5–27.3+ months); 22.1 months in combination (range 2.8–35.2+ months).
  • Tumor regression observed in both injected and non-injected lesions, indicating systemic immune response.
  • No Grade 4 or 5 treatment-related adverse events; safety profile consistent with immune activation.
  • Randomized Phase 2/3 trial in metastatic uveal melanoma (NCT06581406) is enrolling.

Financial Impact

No financial data provided; clinical-stage company with no approved products or revenue.

pipeline valueregulatory probability of success

Risk Factors

  • Phase 2/3 trial may fail to replicate Phase 1 efficacy in a larger, randomized setting.
  • Competition from other oncolytic virus therapies and ICI combinations.
  • No near-term revenue or regulatory filing catalyst; cash burn risk for clinical-stage biotech.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
8% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303918

Track record

32 reports on REPL

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  5. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  6. Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  7. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
  8. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
  10. Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 31, 2026